Publications by authors named "Kelly Slocum"

Claim this Profile
I
Identification of TNO155, an Allosteric SHP2 Inhibitor for the Treatment of Cancer.
Matthew J LaMarche, Michael Acker, Andreea Argintaru, Daniel Bauer, Julie Boisclair, Kelly Slocum

J Med Chem· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optimization of 3-Pyrimidin-4-yl-oxazolidin-2-ones as Orally Bioavailable and Brain Penetrant Mutant IDH1 Inhibitors.
Qian Zhao, James R Manning, James Sutton, Abran Costales, Martin Sendzik, Kelly Slocum

ACS Med Chem Lett· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery and Evaluation of Clinical Candidate IDH305, a Brain Penetrant Mutant IDH1 Inhibitor.
Young Shin Cho, Julian R Levell, Gang Liu, Thomas Caferro, James Sutton, Kelly Slocum

ACS Med Chem Lett· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optimization of 3-Pyrimidin-4-yl-oxazolidin-2-ones as Allosteric and Mutant Specific Inhibitors of IDH1.
Julian R Levell, Thomas Caferro, Gregg Chenail, Ina Dix, Julia Dooley, Kelly Slocum

ACS Med Chem Lett· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
IDH1 mutations alter citric acid cycle metabolism and increase dependence on oxidative mitochondrial metabolism.
Alexandra R Grassian, Seth J Parker, Shawn M Davidson, Ajit S Divakaruni, Courtney R Green, Kelly L Slocum

Cancer Res· June 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthetic silvestrol analogues as potent and selective protein synthesis inhibitors.
Tao Liu, Somarajan J Nair, André Lescarbeau, Jitendra Belani, Stéphane Peluso, Kelly Slocum

J Med Chem· October 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antitumor activity of the Hsp90 inhibitor IPI-504 in HER2-positive trastuzumab-resistant breast cancer.
Maurizio Scaltriti, Violeta Serra, Emmanuel Normant, Marta Guzman, Olga Rodriguez, Kelly L Slocum

Mol Cancer Ther· May 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hsp90 (heat shock protein 90) inhibitor occupancy is a direct determinant of client protein degradation and tumor growth arrest in vivo.
Bonnie Tillotson, Kelly Slocum, John Coco, Nigel Whitebread, Brian Thomas

J Biol Chem· December 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Nf2 tumor suppressor regulates cell-cell adhesion during tissue fusion.
Margaret E McLaughlin, Genevieve M Kruger, Kelly L Slocum, Denise Crowley, Norman A Michaud

Proc Natl Acad Sci U S A· February 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis